I

118TH CONGRESS
1ST SESSION

H. R. 383

To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

JANUARY 17, 2023

Mrs. HARSHBARGER (for herself, Mr. HERN, Mr. LAMBORN, Mr. BAIRD, Mr. CARTER of Georgia, Mr. WEBER of Texas, Mrs. MILLER of Illinois, Mr. BANKS, Mr. JACKSON of Texas, Mr. WEBSTER of Florida, Mr. DUNCAN, Mr. FEENSTRA, Mr. SMITH of New Jersey, and Mr. GOSAR) introduced the following bill; which was referred to the Committee on Energy and Commerce

---

A BILL

To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. NULLIFICATION OF MODIFICATIONS TO REMS FOR MIFEPRISTONE.

(a) NULLIFICATION.—The modifications made by the Food and Drug Administration in January 2023 to the

risk evaluation and mitigation strategy under section 505–1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355–1) for mifepristone are hereby nullified.

(b) NO SUBSTANTIALLY SIMILAR PROVISIONS.—The Secretary of Health and Human Services (or any head of any office, department, or agency of the Department of Health and Human Services) shall not establish, implement, or enforce any provision of a risk evaluation and mitigation strategy under section 505–1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355–1) for mifepristone that is substantially similar to any of the modifications nullified by subsection (a).

○